Details of Q2 FY24 Quarterly Report, Appendix 4C & Webinar
Released
Released
Announcement PDF
ASX Announcement
29 January 2024
Details of Q2 FY24 Quarterly Report, Appendix 4C & Webinar
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) will release its Q2 FY24 Quarterly Activities Report
& Appendix 4C on Tuesday, 30 January 2024.
The Company will host an investor webinar with CEO Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro at 10:00am
AEST / 11:00am AEDT on Tuesday, 30 January 2024.
Presenting: CEO, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro
Time: 10:00am AEST / 11:00am AEDT on Tuesday, 30 January 2024
To register for the session and for more information on the conference click on the below link:
Microba Q2 FY24 Investor Webinar Registration
Investors can submit questions prior to the webinar investor@microba.com or do so via the Q&A functions on Zoom during
the webinar.
This announcement has been authorised for release by the Chairman and CEO.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com
Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions.
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Share your feedback
Discover